About this item:

285 Views | 332 Downloads

Author Notes:

Correspondence: K. I. Votanopoulos, MD, Phd, FACS, kvotanop@wakehealth.edu.

Presented at the Gastrointestinal Cancers Symposium, San Francisco, CA, January 2015.

Conflicts of interest: nothing to disclose.


Research Funding:

Supported by Wake Forest University Biostatistics shared resource NCI CCSG P30CA012197.


  • Science & Technology
  • Life Sciences & Biomedicine
  • Oncology
  • Surgery

Is Linitis Plastica a Contraindication for Surgical Resection: A Multi-Institution Study of the US Gastric Cancer Collaborative

Show all authors Show less authors


Journal Title:

Annals of Surgical Oncology


Volume 23, Number 4


, Pages 1203-1211

Type of Work:

Article | Post-print: After Peer Review


Background: Current staging and treatment guidelines for gastric adenocarcinoma do not differentiate between linitis plastic (LP) and non-LP cancers. Significant controversy exists regarding the surgical management of LP patients. Methods: Using the multi-institutional U.S. Gastric Cancer Collaborative database, 869 gastric cancer patients who underwent resection between 2000 and 2012 were identified. Clinicopathologic and outcomes data of 58 LP patients were compared to 811 non-LP patients. Results: Stage III/IV disease was more common at presentation in LP patients compared with non-LP patients (90 vs. 44 %, p < 0.01). Despite the fact that most LP patients underwent total gastrectomy (88 vs. 39 %, p < 0.01), final positive margins were more common in LP patients (33 vs. 7 %, p < 0.01). The use of frozen section allowed 15 intraoperative positive margins in 38 patients to be converted to negative final margins. Median overall survival (OS) was significantly worse in patients with LP (11.6 vs. 37.8 months, p < 0.01). There was no difference in median OS of LP patients based on stage (I/II, 17.3 mo; III, 10.6 mo; IV, 12.0 mo; p = 0.46). LP and non-LP patients who underwent optimal resection (negative margin and D2/3 lymphadenectomy) had better survival compared with those with nonoptimal resections. The median OS for optimally resected stage III LP (n = 22) and stage III non-LP (n = 185) patients was nearly identical (26.7 vs. 25.3 mo; p = 0.69). Conclusions: Future staging systems and treatment guidelines should differentiate between LP and non-LP gastric cancers. Long-term survival in select LP patients who undergo optimal resections is comparable to optimally resected non-LP patients.

Copyright information:

© Society of Surgical Oncology 2015

Export to EndNote